Table 1.

Clinicopathologic characteristics of osteosarcoma patients analyzed using microarrays

Development of plumonary recurrencePresent (n = 7)Abscent (n = 12)
Gender0.938*
    Male57
    Female25
Age0.233
    Mean (SD)16 (5.3)14 (4.0)
Site of origin0.317*
    Femur, proximal11
    Femur, distal35
    Tibia, proximal23
    Tibia, distal12
    Other01
Histologic subtype0.976*
    Osteoblastic69
    Others13
Metastasis at diagnosis0.976*
    Absent69
    Present13
Neoajuvant chcemotherapy regimen0.347
    MTX+DOX/CDDP55
    IFO+DOX/CDDP25
    Others02
Response to neoadjuvant chemotherapy0.667*
    Good (necrosis ≥90%)26
    Poor (necrosis <90%)56
Duration to the development of pulmonary metastasis (mo)
    Mean (SD)28 (11.6)NA
Disease status<0.001*
    CDF09
    NED31
    DOD42
Follow-up period (mo)0.290
    Mean (SD), mo62 (29.0)72 (31.0)
mRNA expression (microarray-based arbitrary unit), mean (SD)
    VEGF1,151 (661)2,519 (1,709)0.056
    MMP22,645 (1,812)3,019 (2,158)0.837
    MMP96,521 (5,284)7,981 (6,199)0.711
    CXCR4989 (300)844 (456)0.536
    TP53108 (50)74 (39)0.120
    ABCB1 (MDR1)42 (10)36 (5)0.167
    ERBB2 (Her2)199 (96)215 (69)0.331
    BIRC5 (Survivin)424 (216)432 (163)0.711
    VIL2 (Ezrin)574 (213)598 (321)0.837
    WT145 (9.0)42 (5.9)0.612
    LRP548 (11)51 (12)0.482
    FAS303 (266)316 (322)0.837
    ASS86 (41)541 (379)<0.001

NOTE: Wilcoxon test was applied to assess differences in values.

Abbreviations: MTX, methotrexate; DOX, doxorubicin; CDDP, cisplatin; IFO ifosfamideof disease; NA, not applicable; CDF, chronic disease free; NED, no evidence of disease; DOD, deed of disease.

  • *Calculated by χ2 test.